A small Swiss biotech has terminated a mid-stage test of a new type of oral drug for people with Alzheimer's disease, ...

High-rolling investors have positioned themselves bullish on Biogen BIIB, and it's important for retail traders to take note. \This activity came to our attention today through Benzinga's tracking ...

Even with the cheaper entry price, we're cautious about Biogen. Here are three reasons why BIIB doesn't excite us and a stock ...

Switzerland and other EFTA nations—Iceland, Liechtenstein, and Norway—plan to invest USD 100 billion in India over the next 15 years as part of the newly signed Trade and Economic Partnership ...

Biogen Inc. (BIIB), based in Cambridge, Massachusetts, is a leading biotechnology company focused on developing and delivering innovative therapies for neurological and neurodegenerative diseases ...

A cost-saving effort by NHS England to transition multiple sclerosis (MS) patients from Biogen Inc’s (NASDAQ:BIIB) Tysabri (natalizumab) to the biosimilar drug Tyruko has led to significant side ...

Jennifer Veilleux didn’t know what she was getting herself into when she agreed to a winter vacation with friends in Grindelwald, Switzerland. “I got a message from my friend that said ...

Stoke Therapeutics Inc. and Biogen Inc. said Tuesday they are entering a collaboration to develop and commercialize a treatment for Dravet syndrome, a severe form of epilepsy that starts in childhood.